Novo Integrated Sciences Inc
Novo Integrated Sciences, Inc., together with its subsidiaries, provides multidisciplinary primary care and related wellness products and services in Canada. It operates in two segments, Healthcare Services and Product Sales. The company offers physiotherapy, chiropractic care, manual/manipulative therapy, occupational therapy, eldercare, massage therapy, acupuncture and functional dry needling, … Read more
Novo Integrated Sciences Inc (NVOS) - Net Assets
Latest net assets as of November 2024: $14.61 Million USD
Based on the latest financial reports, Novo Integrated Sciences Inc (NVOS) has net assets worth $14.61 Million USD as of November 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($32.14 Million) and total liabilities ($17.53 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $14.61 Million |
| % of Total Assets | 45.47% |
| Annual Growth Rate | N/A |
| 5-Year Change | -50.58% |
| 10-Year Change | 98957.31% |
| Growth Volatility | 18386.36 |
Novo Integrated Sciences Inc - Net Assets Trend (2004–2024)
This chart illustrates how Novo Integrated Sciences Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Novo Integrated Sciences Inc (2004–2024)
The table below shows the annual net assets of Novo Integrated Sciences Inc from 2004 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-08-31 | $14.61 Million | -40.35% |
| 2023-08-31 | $24.50 Million | -44.86% |
| 2022-08-31 | $44.43 Million | +1.42% |
| 2021-08-31 | $43.80 Million | +48.13% |
| 2020-08-31 | $29.57 Million | +15.77% |
| 2019-08-31 | $25.54 Million | +14685.09% |
| 2018-08-31 | $172.77K | +104.03% |
| 2017-08-31 | $-4.29 Million | +39.40% |
| 2016-09-30 | $-7.08 Million | -48063.48% |
| 2016-08-31 | $14.75K | +102.36% |
| 2015-08-31 | $-625.67K | +33.99% |
| 2014-08-31 | $-947.87K | -18.88% |
| 2013-08-31 | $-797.36K | +65.75% |
| 2012-08-31 | $-2.33 Million | -56.03% |
| 2011-08-31 | $-1.49 Million | -25.24% |
| 2010-08-31 | $-1.19 Million | +17.20% |
| 2009-08-31 | $-1.44 Million | -70.46% |
| 2008-08-31 | $-844.10K | -184.59% |
| 2007-08-31 | $-296.61K | +27.52% |
| 2006-08-31 | $-409.22K | -34.13% |
| 2005-08-31 | $-305.08K | 0.00% |
| 2004-08-31 | $-305.08K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Novo Integrated Sciences Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 7989462300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (August 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $19.05K | 0.13% |
| Other Comprehensive Income | $1.41 Million | 9.49% |
| Other Components | $96.66 Million | 649.05% |
| Total Equity | $14.89 Million | 100.00% |
Novo Integrated Sciences Inc Competitors by Market Cap
The table below lists competitors of Novo Integrated Sciences Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
VTCHF
PINK:VTCHF
|
$57.15K |
|
Community Bankers' Corporation
PINK:CTYP
|
$57.15K |
|
Lenskart Solutions Ltd
NSE:LENSKART
|
$57.18K |
|
Sebang Co. Ltd. Pfd. Series 1
KQ:004365
|
$57.19K |
|
Income Financial Trust
TO:INC-UN
|
$57.08K |
|
Nwai
WAR:NWA
|
$57.04K |
|
QLOSR GROUP AB AK B
F:Y57
|
$57.02K |
|
Branded Legacy Inc
PINK:BLEG
|
$56.91K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Novo Integrated Sciences Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 24,815,945 to 14,892,621, a change of -9,923,324 (-40.0%).
- Net loss of 16,128,570 reduced equity.
- Other comprehensive income increased equity by 1,770,127.
- Other factors increased equity by 4,435,119.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-16.13 Million | -108.3% |
| Other Comprehensive Income | $1.77 Million | +11.89% |
| Other Changes | $4.44 Million | +29.78% |
| Total Change | $- | -39.99% |
Book Value vs Market Value Analysis
This analysis compares Novo Integrated Sciences Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.00x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-08-31 | $-5.44 | $0.00 | x |
| 2005-08-31 | $-54.36 | $0.00 | x |
| 2006-08-31 | $-70.73 | $0.00 | x |
| 2007-08-31 | $-48.25 | $0.00 | x |
| 2008-08-31 | $-110.28 | $0.00 | x |
| 2009-08-31 | $-152.39 | $0.00 | x |
| 2010-08-31 | $-80.57 | $0.00 | x |
| 2011-08-31 | $-68.99 | $0.00 | x |
| 2012-08-31 | $-88.84 | $0.00 | x |
| 2013-08-31 | $-24.22 | $0.00 | x |
| 2014-08-31 | $-12.24 | $0.00 | x |
| 2015-08-31 | $-3.85 | $0.00 | x |
| 2016-08-31 | $0.07 | $0.00 | x |
| 2017-08-31 | $-2.40 | $0.00 | x |
| 2018-08-31 | $0.10 | $0.00 | x |
| 2019-08-31 | $11.77 | $0.00 | x |
| 2020-08-31 | $12.86 | $0.00 | x |
| 2021-08-31 | $17.71 | $0.00 | x |
| 2022-08-31 | $1.52 | $0.00 | x |
| 2023-08-31 | $2.44 | $0.00 | x |
| 2024-08-31 | $0.83 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Novo Integrated Sciences Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -108.30%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -121.32%
- • Asset Turnover: 0.41x
- • Equity Multiplier: 2.16x
- Recent ROE (-108.30%) is above the historical average (-913.26%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | 0.00% | 0.00% | 0.00x | 0.00x | $-251.50K |
| 2005 | 0.00% | 0.00% | 0.00x | 0.00x | $-251.50K |
| 2006 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.03 Million |
| 2007 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.44 Million |
| 2008 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.39 Million |
| 2009 | 0.00% | 0.00% | 0.00x | 0.00x | $-838.79K |
| 2010 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.15 Million |
| 2011 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.42 Million |
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.01 Million |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.08 Million |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-792.89K |
| 2015 | 0.00% | -13.84% | 330.45x | 0.00x | $-970.97K |
| 2016 | -18780.68% | -37.11% | 267.84x | 1.89x | $-2.77 Million |
| 2016 | 0.00% | -4.74% | 2.48x | 0.00x | $367.08K |
| 2017 | 0.00% | -2.07% | 1.44x | 0.00x | $261.88K |
| 2018 | -1046.73% | -23.70% | 1.88x | 23.55x | $-2.13 Million |
| 2019 | -1.53% | -4.16% | 0.29x | 1.26x | $-2.95 Million |
| 2020 | -16.59% | -62.53% | 0.22x | 1.19x | $-7.88 Million |
| 2021 | -10.17% | -47.95% | 0.15x | 1.41x | $-8.85 Million |
| 2022 | -74.47% | -281.52% | 0.16x | 1.62x | $-37.48 Million |
| 2023 | -53.25% | -105.11% | 0.35x | 1.43x | $-15.70 Million |
| 2024 | -108.30% | -121.32% | 0.41x | 2.16x | $-17.62 Million |
Industry Comparison
This section compares Novo Integrated Sciences Inc's net assets metrics with peer companies in the Medical Care Facilities industry.
Industry Context
- Industry: Medical Care Facilities
- Average net assets among peers: $250,407,165
- Average return on equity (ROE) among peers: -38.80%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Novo Integrated Sciences Inc (NVOS) | $14.61 Million | 0.00% | 1.20x | $57.13K |
| Addus HomeCare Corporation (ADUS) | $113.86 Million | 16.82% | 0.44x | $1.75 Billion |
| agilon health Inc (AGL) | $126.73 Million | -319.84% | 9.03x | $166.17 Million |
| Airsculpt Technologies Inc (AIRS) | $123.68 Million | 6.13% | 0.45x | $16.62 Million |
| Amedisys Inc (AMED) | $454.23 Million | -18.40% | 0.61x | $3.26 Billion |
| AMN Healthcare Services Inc (AMN) | $347.86 Million | 23.54% | 1.53x | $624.22 Million |
| American Shared Hospital Service (AMS) | $20.85 Million | 8.48% | 1.33x | $7.93 Million |
| American Oncology Network Inc. (AONC) | $226.04 Million | -0.05% | 0.10x | $112.23 Million |
| Ardent Health Partners, Inc. (ARDT) | $1.08 Billion | 4.65% | 3.71x | $225.22 Million |
| Arem Pacific Corporation (ARPC) | $-45.09K | 0.00% | 0.00x | $246.12K |
| Astrana Health Inc (ASTH) | $8.55 Million | -109.27% | 1.29x | $1.08 Billion |